Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: contrarian who wrote (1352)	11/11/1997 1:22:00 AM
From: Howard Hoffman	Read Replies (1) \| Respond to of 1762

During the big October correction, IDPH touched 32 for a second or two. Many analysts have pointed out that correction lows are usually retested. It feels like that is where we are headed. Short-term, this might pull IDPH as low as 32 (no guarantees that it will not penetrate 32 to go lower still). Longer term, we are still waiting to see what impact FDA approval has on the stock (back to the 40s?) and then we will have to wait and see how the earnings develop so IDPH can be judged like most normal companies. Bottom line: it could be rocky for a bit, but hang on for the good part to come.